WIRE — The University of Oxford has launched the first human trial of a new vaccine designed to protect against Bundibugyo ebolavirus, as scientists race to develop a vaccine for the strain responsible for the ongoing Ebola outbreak. The Phase I clinical trial will involve 50 healthy volunteers aged between 18 and 55 and will be carried The post 50 healthy volunteers aged 18–55 needed for first Bundibugyo Ebola Vaccine trial first appeared on Matooke Republic.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.